ERBB2 and ductal breast carcinoma in situ: We confirmed that regardless of DCIS, DCIS-Mi or HER2+ BC patients, no statistically significant correlation between TILs and DFS was observed (in HER2+ group: HR 0.908 comparing ≤ 5% vs. 5–40%, 95% CI 0.196–4.210; and 1.765 comparing ≤ 5% vs. ≥ 40%, 95% CI, 0.309–10.077).